/compare — side-by-sideLOADING

compare stocks // side-by-side, from filings

Compare any stocks, on the real numbers

Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.

Metric	ALLRAllarity Therapeutic
Last close	$1.08close 2026-11-04
Change %	-4.42%close 2026-11-04
Market cap	$17Mclose 2026-11-04
P/E	loss, no P/E
Revenue	$320000 ⊙ EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerIncludingAssessedTax As ofFY ending 2025-12-31 Filing10-K · 0001437749-26-010310 · filed 2026-03-30 Open the filing on EDGAR →Open the XBRL payload → CiteAllarity Therapeutics, Inc. (ALLR), us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax: 320,000 USD, fiscal year ended 2025-12-31. Form 10-K, accession 0001437749-26-010310, filed 2026-03-30. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001860657/us-gaap/RevenueFromContractWithCustomerIncludingAssessedTax.json

Share this comparisonSend ALLR side-by-side — free, straight from the filings.

Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.